Official Title
Comorbidities And Complications Associated With Covid-19 Infection
Brief Summary

To evaluate the spectrum of comorbidities and complications and its impact on theclinical outcome in hospitalized patients with coronavirus disease 2019 (COVID-19).

Detailed Description

Severe acute respiratory syndrome (SARS) coronavirus 2 (SARS-CoV-2) is a coronavirus with
human infection designated as COVID-19 by the World Health Organization. Bats and birds
serve as the typical coronavirus hosts, with zoonotic spread and a long-documented
history of animal-animal-human transmission.

Since November 2019, the rapid outbreak of coronavirus disease 2019 (COVID-19), which
arose from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, has
recently become a public health emergency of international concern. COVID-19 has
contributed to an enormous adverse impact globally.

As of 10 March 2020 there have been 113702 laboratory confirmed cases and 4012 deaths
globally.

According to the latest reports, the clinical manifestations of COVID-19 are
heterogeneous. On admission, 20-51% of patients were reported as having at least one
comorbidity, with diabetes (10-20%), hypertension (10-15%) and other cardiovascular and
cerebrovascular diseases (7-40%) being most common. Previous studies have demonstrated
that the presence of any comorbidity has been associated with a 3.4-fold increased risk
of developing acute respiratory distress syndrome in patients with H7N9 infection. As
with influenza, SARS-CoV and Middle East Respiratory Syndrome coronavirus (MERS-CoV),
COVID-19 is more readily predisposed to respiratory failure and death in susceptible
patients.

Although it is well documented that COVID-19 is primarily manifested as a respiratory
tract infection, emerging data indicate that it should be regarded as a systemic disease
involving multiple systems, including cardiovascular, respiratory, gastrointestinal,
neurological, hematopoietic and immune system. Mortality rates of COVID-19 are lower than
SARS and Middle East Respiratory Syndrome (MERS); however, COVID-19 is more lethal than
seasonal flu.

Older people and those with comorbidities are at increased risk of death from COVID-19,
but younger people without major underlying diseases may also present with potentially
lethal complications such as fulminant myocarditis and disseminated intravascular
coagulopathy (DIC).

Unknown status
COVID19

Other: complication

complication co morbidities

Eligibility Criteria

Inclusion Criteria:

Patients presented by respiratory symptom and admitted to Assuit university hospitals in
wards and intensive care units due to COVID-19 according to WHO and Egyptian Ministry of
Health and Population (MOH) definitions with positive PCR result.

Exclusion Criteria:

- Negative PCR result for suspicious cases of Covid-19,

- Patients refusing to participate in the study.

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years ~ Maximum: 100 Years
Contacts

Mahmoud Gamal hussein
01004025057
memog919@gmail.com

Gamal Mohamed Rabee
01221729476
Gamalagmy135@gmail.com

Gamal Mohamed Rabee, Proffessor, Study Chair
Assuit university hospital

Assiut University
NCT Number
MeSH Terms
COVID-19